It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
SARS-CoV-2 is the pathogen responsible for COVID-19 that has claimed over six million lives as of July 2022. The severity of COVID-19 motivates a need to understand how it could evolve to escape potential treatments and to find ways to strengthen existing treatments. Here, we used the molecular modeling methods MD + FoldX and PyRosetta to study the SARS-CoV-2 spike receptor binding domain (S-RBD) bound to two neutralizing antibodies, B38 and CB6 and generated lists of antibody escape and antibody strengthening mutations. Our resulting watchlist contains potential antibody escape mutations against B38/CB6 and consists of 211/186 mutations across 35/22 S-RBD sites. Some of these mutations have been identified in previous studies as being significant in human populations (e.g., N501Y). The list of potential antibody strengthening mutations that are predicted to improve binding of B38/CB6 to S-RBD consists of 116/45 mutations across 29/13 sites. These mutations could be used to improve the therapeutic value of these antibodies.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 University of Idaho, Institute for Modeling Collaboration and Innovation, Moscow, USA (GRID:grid.266456.5) (ISNI:0000 0001 2284 9900)
2 University of Idaho, Institute for Modeling Collaboration and Innovation, Moscow, USA (GRID:grid.266456.5) (ISNI:0000 0001 2284 9900); University of Idaho, Department of Biological Sciences, Moscow, USA (GRID:grid.266456.5) (ISNI:0000 0001 2284 9900)
3 University of Idaho, Institute for Modeling Collaboration and Innovation, Moscow, USA (GRID:grid.266456.5) (ISNI:0000 0001 2284 9900); University of Idaho, Department of Physics, Moscow, USA (GRID:grid.266456.5) (ISNI:0000 0001 2284 9900)